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Abstract Sildenafil, a potent and selective inhibitor of phos-
phodiesterase type 5, is used clinically to treat erectile dys-
function and pulmonary arterial hypertension. It is often taken
by patients suffering from depression and receiving antide-
pressant drug treatment. However, its influence on the efficacy
of antidepressant treatment was not sufficiently studied.
Therefore, the aim of the present study was to investigate the
influence of sildenafil on the anti-immobility action of several
antidepressant drugs (i.e., sertraline, fluvoxamine, citalopram,
maprotiline, trazodone, and agomelatine) as well as on
antidepressant-like effect of electroconvulsive stimulations
in the forced swim test in mice. The obtained results showed
that acute sildenafil treatment enhanced the antidepressant-
like activity of all of the studied drugs. The observed effects
were not due to the increase in locomotor activity. The inter-
actions between sildenafil and sertraline, maprotiline, and
trazodone were pharmacodynamic in nature, as sildenafil did
not affect concentrations of these drugs neither in serum nor in
brain tissue. Increased concentrations of fluvoxamine,
citalopram, and agomelatine in brain tissue evoked by silden-
afil co-administration suggest that pharmacokinetic interac-
tions between sildenafil and these drugs are very likely.
Sildenafil injected acutely did not alter the antidepressant-
like efficacy of electroconvulsive stimulations in mice, as
assessed in the forced swim test. Interestingly, repeated
(14 days) administration of sildenafil decreased the anti-
immobility action of the electroconvulsive stimulations. In
conclusion, the present study shows that sildenafil may alter
the effectiveness of antidepressant treatment. Further studies
are warranted to better characterize the influence of sildenafil
on the activity of antidepressant drugs and electroconvulsive
therapy.
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Abbreviations
BDNF Brain-derived neurotrophic factor
cGMP Cyclic guanosine 3′,5′-monophosphate
ECS Electroshock stimulation
ECT Electroconvulsive therapy
HPLC High-performance liquid chromatography
i.p. Intraperitoneally
IS Internal standard
NO Nitric oxide
PDE5 Phosphodiesterase type 5
SEM Standard error of the mean
SSRIs Selective serotonin reuptake inhibitors
Introduction
Major depressive disorder, also known as major depression, is
the most common mental disorder that is the leading cause of
disability worldwide. In the USA, the total economic burden
of major depression was estimated to be $210.5 billion per
year (Greenberg et al. 2015). Antidepressant drugs, first intro-
duced in the 1950s, remain the mainstay of treatment of
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depression and are one of the most widely taken medicines
(Lopez-Munoz and Alamo 2009). High rates of comorbidity
between depression and various somatic and/or mental ill-
nesses result in a need for simultaneous treatment with anti-
depressants and other medications. This requires special cau-
tion, especially concerning drug interactions (Kang et al.
2015; Lopez-Munoz and Alamo 2009; Iosifescu et al. 2004).
For severe and life-threatening depression that does not re-
spond to antidepressants drugs, electroconvulsive therapy
(ECT) is frequently used (Payne and Prudic 2009).
Various studies have shown that depression often co-occurs
with erectile dysfunction. The incidence of these two condi-
tions ranges from 18 to 35%. In severe depression, erectile
dysfunction may be as high as 90% (Farre et al. 2004).
Sildenafil citrate, a selective and competitive inhibitor of
phosphodiesterase type 5 (PDE5), is the first-line oral treat-
ment for erectile dysfunction (Rosen and McKenna 2002). It
was shown to be effective in men with co-occurring depres-
sion and erectile dysfunction, including those taking antide-
pressants (Nurnberg et al. 2002; Seidman et al. 2001).
Sildenafil has also a well-proven efficacy against erectile dys-
function evoked by antidepressant therapy, mainly with selec-
tive serotonin reuptake inhibitors (SSRIs) (Nurnberg and
Hensley 2003). Men suffering from depression and erectile
dysfunction are not the only group of patients who may be
taking antidepressants and sildenafil. Of note, sildenafil was
reported to reduce antidepressant-associated sexual dysfunc-
tion in women (Nurnberg et al. 2008). Moreover, sildenafil is
one of the management strategies for the treatment of pulmo-
nary arterial hypertension (Wang et al. 2014) that is a rare and
debilitating disease with concomitant depressive symptoms
estimated at ~55% (McCollister 2011).
Although sildenafil is often used in patients treated with
antidepressant drugs, there is no clear-cut evidence that it
augments or worsens antidepressant action in humans. In
clinical trials evaluating the efficacy of sildenafil against
antidepressant-associated erectile dysfunction, mean de-
pression scores were consistent with remission evoked by
antidepressant therapy in both placebo- and sildenafil-
treated groups (Nurnberg and Hensley 2003; Nurnberg
et al. 2003). Data obtained from animal studies are, howev-
er, quite controversial. Since sildenafil works via the nitric
oxide/cyclic guanosine 3′,5′-monophosphate (NO/cGMP)
pathway (Rosen and McKenna 2002), it is often used as a
pharmacological tool to study the role of this signaling path-
way in the mechanism of action of various compounds, in-
cluding antidepressants. For example, sildenafil was shown
to abolish the antidepressant-like effect of memantine
(Almeida et al. 2006), lithium (Ghasemi et al. 2008),
escitalopram (Zomkowski et al. 2010), duloxetine
(Zomkowski et al. 2012), and paroxetine (Socała et al.
2012d) in the forced swim test in mice, whereas it failed to
reverse the antidepressant effect of fluoxetine in rats (Brink
et al. 2008). Interestingly, sildenafil at a relatively small dose
(5 mg/kg) reversed the antidepressant action of bupropion
(Dhir and Kulkarni 2007b) and venlafaxine (Dhir and
Kulkarni 2007a), while in another study, when injected at
higher doses (10–20 mg/kg), it was reported to enhance the
anti-immobility effect of bupropion and venlafaxine in mice
(Socała et al. 2012a). Furthermore, sildenafil caused a potent
enhancement of the activity of amitriptyline (a tricyclic an-
tidepressant that exhibits cholinolytic properties), but with-
out affecting the activity of desipramine—a tricyclic antide-
pressant devoid of antimuscarinic action (Socała et al.
2012c). The anti-immobility action of two atypical antide-
pressants, mianserin and tianeptine, was also enhanced by
sildenafil co-administration (Socała et al. 2012b). It is worth
noting that the sildenafil-induced potentiation of the
antidepressant-like effects of bupropion, venlafaxine, and
tianeptine might have been, at least in part, due to pharma-
cokinetic interactions between these drugs and sildenafil
(Socała et al. 2012a, b).
Thus, sildenafil appears to exert various effects on the ac-
tivity of antidepressant drugs depending on the mechanism of
action of the respective drug, the dose of sildenafil used, and/
or other yet unidentified factors. It seems that the interactions
between sildenafil and antidepressants should be estimated for
each drug individually. Therefore, the aim of the present study
was to evaluate the influence of sildenafil on the activity of
other antidepressant drugs (i.e., sertraline, fluvoxamine,
citalopram, maprotiline, trazodone, and agomelatine) in the
forced swim test in mice. In addition, we aimed to investigate
the impact of sildenafil on the antidepressant effect of the
repeated electroshock stimulation (ECS) which mimics the
ECT therapy in humans. Moreover, plasma and brain concen-
trations of antidepressant drugs were measured to determine
any pharmacokinetic contribution to the observed behavioral
effects.
Materials and methods
Animals
Experimentally naïve male albino Swiss mice weighing
25–30 g were used in all experiments. The animals were
purchased from a licensed breeder (Laboratory Animals
Breeding, Ilkowice, Poland) and housed in groups of eight
in Makrolon cages (37 cm × 21 cm × 14 cm) under strictly
controlled laboratory conditions (temperature maintained at
21–24 °C, relative humidity 45–65%) with an artificial 12/
12-h light/dark cycle (lights on at 6:00 a.m.). A nutritional-
ly balanced rodent chow diet (Murigran; Agropol S.J.,
Motycz, Poland) and tap water were continuously avail-
able. Animals were used in the study after at least 1 week
of acclimatization. All experiments were performed
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between 8:00 a.m. and 2:00 p.m., after a minimum 30-min
acclimatization period to the conditions kept in the experi-
mental room. The animals were randomly assigned to the
experimental groups. Each animal was used only once.
The study was performed under experimental protocols ap-
proved by the Ethical Committee of the Medical University in
Lublin. Housing and experimental procedures were conducted
in accordance with the European Union Directive of 22
September 2010 (2010/63/EU) and Polish legislation acts
concerning animal experimentation. All efforts were made to
minimize animal suffering as well as the number of animals
used in the study.
Drugs and treatments
Sildenafil citrate (kindly provided by Polpharma S.A.,
Starogard Gdański, Poland) was dissolved in a 1% aqueous
solution of Tween 80 (POCH, Gliwice, Poland), citalopram
hydrobromide (Cipramil; Lundbeck GmbH, Hamburg,
Germany) and trazodone hydrochloride (Sigma-Aldrich, St.
Louis, MO, USA) were dissolved in normal saline, whereas
sertraline hydrochloride (Miravil; Orion Pharma, Espoo,
Finland), fluvoxamine maleate (Fevarin; Abbott Healthcare
SAS, Châtillon-sur-Chalaronne, France), maprotiline hydro-
chloride (Ludiomil; Amdipharm Limited, Dublin, Ireland),
and agomelatine (Valdoxan; Servier, Suresnes, France) were
suspended in a 0.5% aqueous solution of methyl cellulose
(Sigma, Steinheim, Germany). The pretreatment time for sil-
denafil, citalopram, trazodone, and maprotiline was 30 min,
while sertraline, fluvoxamine, and agomelatine were injected
60 min before the tests. In studies dealing with the effect of
sildenafil on the repeated ECS procedure, sildenafil was ad-
ministered acutely 30 min before the behavioral tests or re-
peatedly every 24 h for 14 consecutive days. In the subchron-
ic studies, all experiments were performed 24 h after the last
injection in order to avoid acute effects of the drug on animal
behavior (Dadomo et al. 2013). All drug solutions/
suspensions were prepared freshly and administered intraper-
itoneally (i.p.) at a volume of 0.1 ml per 10 g of body weight.
Control animals received a combination of respective vehi-
cles. In studies assessing the effect of repeated (14 days) sil-
denafil treatment on the efficacy of the ECS procedure, ani-
mals from the sham (control) group and from the ECS-treated
group were injected with vehicle repeatedly every 24 h for 14
consecutive days.
The doses and pretreatment schedules were based on
those reported in the literature and on previous experiments
in our laboratory. The initial dose for sildenafil treatment
was 20 mg/kg. The dose was then increased or decreased
depending on the observed effect. To avoid repetition, the
effect of sildenafil administered alone was not investigated
in the present study.
Electroconvulsive stimulation
Electroconvulsive stimuli (0.75-ms duration pulses at 100 Hz
for 0.5 s, current intensity 10–16 mA) were delivered via
saline-soaked corneal electrodes using a Grass model CCU1
constant current unit coupled to a Grass S48 stimulator (Grass
Technologies, Warwick, RI, USA). Before stimulation, the
corneal electrodes were wetted with saline to provide good
electrical contact. The criterion for successful ECS was the
presence of generalized tonic–clonic convulsions lasting for
5–10 s. To prevent death due to respiratory failure, mice were
placed to a box filled with pure oxygen for 3 min before the
ECS and immediately after the ECS. Despite oxygen supply,
several mice died after seizure. Mice from the sham (control)
group were subjected to the same procedures but without de-
livering the electric current. The animals were subjected to the
ECS every other day for 2 weeks, with a total of seven treat-
ments. Behavioral tests were performed 24 h after the last
ECS.
The forced swim test
The test procedure was performed following the method de-
scribed by Porsolt et al. (1977). Mice were placed individually
into glass cylinders (height 25 cm, diameter 10 cm) containing
11 cm of water maintained at a temperature of 23–25 °C.
Animals were allowed to swim for 6 min. After the initial
2 min of vigorous activity, the total duration of immobility
was recorded during the last 4 min of the test. Mice were
considered immobile when they stopped struggling, remained
floating passively, made no attempts to escape, and showed
only slow limb movements necessary to keep its head above
the water.Water in the beakers was changed regularly between
subjects. The immobility time was recorded by a trained ob-
server who was aware of the nature of the treatment, with the
help of cumulative stopwatches. Data obtained in groups of
10–12 mice were expressed as means (in s) ± standard error of
the mean (SEM).
The locomotor activity test
To monitor the spontaneous locomotor activity of mice, an
IR Actimeter system (Panlab/Harvard Apparatus,
Barcelona, Spain) was used. This consisted of a square arena
(25 × 25 cm) surrounded by a frame containing a total of
16 × 16 infrared beams located on the sides. The frame was
coupled to a computerized control unit. Mice were placed
individually in the actimeter, in which they were allowed to
explore freely for 6 min. The arena was cleaned thoroughly
with a 0.1% acetic acid solution before each mouse was
placed in it. Locomotor activity was defined as a horizontal
activity with displacement and was expressed in terms of a
total number of interruptions of the photo beams within the
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last 4 min of the test, which corresponds to the time interval
analyzed in the forced swim test. Interruptions of the photo
beams were recorded automatically and analyzed with a
computerized system (SedaCom32; Panlab/Harvard
Apparatus, Barcelona, Spain). Data obtained in groups of
9–12 mice were expressed as means of activity counts/
4 min ± SEM.
Determination of antidepressant concentrations
Thirty minutes following administration of citalopram,
maprotiline, and trazodone and 60 min following adminis-
tration of sertraline, fluvoxamine, and agomelatine with or
without sildenafil, mice were decapitated to collect biolog-
ical material for pharmacokinetic studies. Blood was col-
lected into Eppendorf tubes and allowed to clot at room
temperature. Subsequently, it was centrifuged at 5600 rpm
for 10 min and serum was collected into polyethylene tubes.
Immediately after the decapitation, brains were dissected
from the skull and washed with 0.9% NaCl. The samples
were kept at −25 °C until analysis.
Serum and brain concentrations of all antidepressants
studied were measured by a high-performance liquid chro-
matography (HPLC) method. The brains were homoge-
nized in distilled water (1:4, w/v) with a tissue homogenizer
TH220 (Omni International, Inc., Warrenton, VA, USA).
The extraction of most drugs studied from serum and brain
homogenates was performed using the ethyl acetate/hexane
(30:70, v/v) mixture. Paroxetine (200 ng/ml) was used as an
internal standard (IS) for trazodone, citalopram, and sertra-
line; trazodone (500 ng/ml) for maprotiline; desipramine
(250 ng/ml) for fluvoxamine; and carbamazepine (100 ng/
ml) for agomelatine. In order to isolate citalopram,
fluvoxamine, maprotiline, sertraline, and trazodone, to se-
rum (50–100 μl) or brain homogenate (100–250 μl) con-
taining these drugs, an appropriate IS was added and the
samples were alkalized with 50 μl of 4 M NaOH. Then,
the samples were extracted with 1 ml of the extraction re-
agent by shaking for 20 min (IKAVibrax VXR, Germany).
After centrifugation for 4 min (Abbott Diagnostics Division
TDX/TM centrifuge), the organic layers were transferred to
new Eppendorf tubes containing a 100 μl solution of 0.1 M
H2SO4 and methanol (90:10, v/v), shaken for 20 min, and
then centrifuged for 4 min. The organic layers were
discarded, and the aliquots (10 μl) of acidic solutions were
injected into the HPLC system.
Agomelatine was extracted with 1 or 5 ml of dichloro-
methane as the extraction reagent from 200 μl of serum or
1 ml of brain homogenate, respectively, after the addition
of IS. In order to precipitate proteins, 1 ml of the concen-
trated NaCl solution (10 g/50 ml) was added to brain
homogenate before the extraction and the samples were
vortexed for 15 s. Then, both serum and homogenate
samples were shaken for 20 min (IKA Vibrax VXR,
Germany) and centrifuged for 15 min at 3000 rpm
(Universal 32, Hettich, Germany). Subsequently, the organ-
ic layers were transferred into conical glass tubes and evap-
orated to dryness at 37 °C under a gentle stream of nitrogen
in a water bath. The residues were dissolved with 100 μl of
methanol, and 50 μl of these solutions was injected into the
HPLC system.
The HPLC system (Merck Hitachi, Darmstadt, Germany)
consisted of an L-7100 isocratic pump, an L-7200
autosampler, and a UV variable-wavelength K-2600 detec-
tor (Knauer, Berlin, Germany). D-7000 HSM software was
used for data acquisition and processing. Analyses of most
drugs were performed on a 250 × 4.6 mm Supelcosil LC-CN
column with a particle size of 5 μm (Sigma-Aldrich,
Steinheim, Germany) protected with a guard column
(20 × 4 mm) with the same packing material. The only ex-
ception was agomelatine which was separated using a
250 × 4mmLiChrospher® 100RP-18 columnwith a particle
size of 5 μm (Merck, Darmstadt, Germany) protected with a
LiChrospher RP-18 guard column (4 × 4 mm). The mobile
phase consisting of acetonitrile and 50 mM potassium
dihydrogen phosphate was mixed at a ratio of 21:79 (v/v)
for maprotiline, sertraline, and trazodone; 25:75 (v/v) for
citalopramand fluvoxamine; and35:65 (v/v) for agomelatine
and was run at 1 ml/min. Chromatographic analyses were
carried out at 21 °C and the analytical wavelength was
240 nm for citalopram, 230 nm for agomelatine, and
214 nm for the remaining antidepressants studied.
The calibration curves were constructed by plotting the
ratio of the peak heights of the studied drug to IS versus drug
concentration, and they were linear in the tested concentra-
tion ranges.The assayswere reproduciblewith low intra- and
inter-day variation (coefficient of variation less than 10%).
The extraction efficiencies of the analyzed compounds and
internal standards ranged from 70 to 92%. No interfering
peakswere observed in the blank serumor brain homogenate
in the regions of interest. Similarly, sildenafil did not inter-
fere with the developedmethods. Antidepressant concentra-
tions were expressed in nanograms per milliliter of serum or
micrograms per gram of wet brain tissue.
Statistical analysis
Data obtained in behavioral tests were evaluated by using one-
way analysis of variance (one-way ANOVA) followed by
Tukey’s post hoc test formultiple comparisons.Concentrations
of the tested antidepressant drugs were compared by unpaired
Student’s t test.Statistical significancewasnotedwhenpvalues
were equal toor less than0.05.All calculationswere carried out
with GraphPad Prism, version 5.03, for Windows (GraphPad
Software,SanDiego,CA,USA).
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Results
Effect of sildenafil on the activity of antidepressant drugs
in the forced swim test
The effect of sildenafil on the antidepressant-like activity of
sertraline in the forced swim test in mice is shown in Fig. 1a
(one-way ANOVA: F(4, 55) = 30.86, p < 0.0001).
Sertraline administered alone at a dose of 20 mg/kg signif-
icantly shortened the total immobility duration as compared
to the control group (p < 0.001). Co-administration of ser-
traline and sildenafil at a dose of 10 mg/kg caused ~50%
decrease in the immobility time as compared to the
sertraline-treated group (p < 0.01), while joint administra-
tion of sertraline and sildenafil at a dose of 20 mg/kg caused
over 75% decrease in immobility time as compared to ser-
traline given alone (p < 0.001). Sildenafil at the lowest dose
tested, i.e., 5 mg/kg, did not affect the antidepressant-like
effect of sertraline.
The effect of sildenafil on the antidepressant-like activity
of fluvoxamine in the forced swim test in mice is shown in
Fig. 1b (one-way ANOVA: F(4, 52) = 16.05, p < 0.0001).
Fluvoxamine administered alone at a dose of 40 mg/kg sig-
nificantly reduced the immobility time as compared to the
control group (p < 0.05). Sildenafil injected at doses of 20
and 30 mg/kg augmented the anti-immobility action of
fluvoxamine by ~30% (p < 0.05 and p < 0.01 vs. the
fluvoxamine-treated group, respectively). Co-administration
of fluvoxamine and sildenafil at a dose of 10 mg/kg did not
cause any additional effects on the total immobility duration
as compared to the fluvoxamine-treated group.
The effect of sildenafil on the antidepressant-like activity
of citalopram in the forced swim test in mice is shown in
Fig. 1c (one-way ANOVA: F(4, 51) = 21.15, p < 0.0001).
Citalopram administered alone at a dose of 25 mg/kg sig-
nificantly reduced the total immobility duration as com-
pared to the control group (p < 0.01). Sildenafil at the lowest
dose tested, i.e., 10 mg/kg, did not affect the anti-
immobility effect of citalopram. At a dose of 20 mg/kg,
sildenafil significantly enhanced the antidepressant-like ac-
tivity of citalopram (p < 0.05 as compared to the citalopram-
treated group). The highest dose of sildenafil (30 mg/kg)
caused ~50% increase in the anti-immobility action of
citalopram (p < 0.001 vs. the citalopram-treated group).
The effect of sildenafil on the antidepressant-like activ-
ity of maprotiline in the forced swim test in mice is shown
in Fig. 1d (one-way ANOVA: F(4, 55) = 21.60, p < 0.0001).
Maprotiline administered alone at a dose of 40 mg/kg sig-
nificantly reduced the total immobility duration (p < 0.001
vs. the control group). Joint administration of maprotiline
and sildenafil at the lowest dose tested, i.e., 20 mg/kg, did
not cause any additional effect on the immobility time as
compared to the maprotiline-treated group. However, when
injected at higher doses (30 and 40 mg/kg), sildenafil aug-
mented the antidepressant-like effect of maprotiline by
~35% (p < 0.05 vs. the maprotiline-treated group for both
experimental groups).
The effect of sildenafil on the antidepressant-like activity
of trazodone in the forced swim test in mice is shown in
Fig. 1e (one-way ANOVA: F(4, 54) = 11.36, p < 0.0001).
Trazodone administered alone at a dose of 10 mg/kg as well
as trazodone in combination with sildenafil at a dose of
20 mg/kg did not alter the total immobility duration as com-
pared to the control group. However, joint administration of
trazodone with sildenafil at doses of 30 and 40 mg/kg pro-
duced ~20% reduction in the immobility time as compared
to the control group (p < 0.01 and p < 0.001, respectively)
and as compared to the trazodone-treated group (p < 0.001
for both experimental groups).
The effect of sildenafil on the antidepressant-like activity
of agomelatine in the forced swim test in mice is shown in
Fig. 1f (one-way ANOVA: F(4, 53) = 10.41, p < 0.0001).
Neither agomelatine administered alone at a dose of 30 mg/
kg nor joint administration of agomelatine and sildenafil at a
dose of 10 mg/kg affected the total immobility duration as
compared to the control group. Co-administration of
agomelatine with sildenafil at a dose of 20 mg/kg reduced
the immobility time by ~15% as compared to both
agomelatine-treated and control groups (p < 0.05 and
p < 0.01, respectively). Sildenafil injected at a dose of
30 mg/kg caused further (~20%) reduction in the immobility
duration (p < 0.001 as compared to the agomelatine- and
vehicle-treated groups).
Effect of sildenafil on antidepressant action of repeated
ECS in the forced swim test
The influence of acute and subchronic treatments with sil-
denafil on the antidepressant-like effect of the repeated
ECS in the forced swim test in mice is shown in Fig. 2
(one-way ANOVA: F(4, 51) = 13.80, p < 0.0001, in
Fig. 2a and F(4, 54) = 25.75, p < 0.0001, in Fig. 2b). The
repeated ECS resulted in a significant anti-immobility ef-
fect as compared to the sham group (p < 0.001 in both acute
and subchronic studies vs. the sham group). Sildenafil ad-
ministered acutely at doses of 20, 30, and 40 mg/kg did not
affect the immobility time as compared to the ECS-treated
animals. Subchronic administration of sildenafil at a dose
of 20 mg/kg did not affect the anti-immobility effect of the
ECS procedure. However, a higher dose of sildenafil
(30 mg/kg) significantly weakened the antidepressant-like
effect of the ECS (p < 0.001 vs. the ECS-treated group;
p < 0.05 vs. the sham group), while at the highest dose
tested (40 mg/kg), sildenafil entirely abolished the anti-
immobility action of the ECS procedure (p < 0.001 vs.
the ECS-treated group).
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Effect of treatments on spontaneous locomotor activity
in mice
Data obtained in the spontaneous locomotor activity test in
mice is presented in Table 1 (one-way ANOVA: F(6,
63) = 8.684, p < 0.0001, for a; F(6, 60) = 28.22, p < 0.0001,
for b; F(2, 32) = 0.762, p = 0.475, for c; and F(2, 28) = 6.784,
p = 0.004 for d). Sertraline, citalopram, and fluvoxamine ad-
ministered alone as well as in combination with sildenafil did
not affect the locomotor activity in mice. Agomelatine admin-
istered alone had no significant effect on the activity counts,
while agomelatine co-administered with sildenafil reduced the
locomotor activity in mice as compared to the control group
(p < 0.001). Maprotiline and trazodone administered either
alone or in combination with sildenafil produced a marked
decrease of the locomotor activity (p < 0.001 vs. the control
group).
In studies assessing acute effects of sildenafil on the activ-
ity of the ECS procedure, no significant alterations in the
locomotor activity in mice subjected to the ECS procedure
were noticed. Likewise, sildenafil administered acutely to
the ECS-treated mice did not produce any significant changes
in spontaneous locomotor activity.
Unexpected results were obtained in studies dealing with
the influence of subchronic (14 days) sildenafil treatment on
the effect of the ECS procedure. Mice subjected to the ECS
procedure and vehicle treatment (14 days) as well as mice
subjected to the ECS procedure and sildenafil treatment
(14 days) exhibited a decreased locomotor activity in compar-
ison to the control group, i.e., injected with vehicle only for
14 days (p < 0.05 and p < 0.01, respectively).
Pharmacokinetic studies
The effect of sildenafil on serum and brain concentrations of
the tested antidepressant drugs in mice is shown in Table 2.
Sildenafil significantly increased brain concentrations of
fluvoxamine and citalopram (p < 0.001 and p < 0.01, respec-
tively) without affecting their concentrations in the serum. Co-
administration of sildenafil with agomelatine caused a signif-
icant increase in agomelatine concentration in both serum and
brain tissue (p < 0.05 and p < 0.01, respectively). Sildenafil
did not produce any changes in the concentrations of sertra-
line, maprotiline, and trazodone neither in serum nor in brain
tissue.
Fig. 1 a–f Effects of
antidepressant drugs administered
alone and in combination with
sildenafil on the immobility time
in the forced swim test in mice.
Sildenafil, citalopram,
maprotiline, and trazodone were
injected 30 min before the test,
while sertraline, fluvoxamine, and
agomelatine 60 min before the
test. Control animals received
vehicles only. Each experimental
group consisted of 10–12
animals. Data are presented as
means + SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, as
compared to the control group;
#p < 0.05, ##p < 0.01,
###p < 0.001, as compared to the
antidepressant-treated group
(one-way ANOVA followed by
Tukey’s post hoc test)
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Discussion
Sildenafil was developed as an orally active vasodilator that
prolongs the effect of cGMP by selectively inhibiting PDE5
in blood vessels. Its action is not limited only to peripheral
tissues. The drug crosses the blood–brain barrier and exerts
versatile central effects (Uthayathas et al. 2007). Since the
NO/cGMP/PDE5 signaling pathway is implicated in the
neurobiology of mood disorders, it is possible that sildenafil
influences depressive symptoms and the therapeutic poten-
tial of antidepressant drugs.
Several previous studies showed that sildenafil produced
various effects on the activity of antidepressant drugs in
animals. Sildenafil was shown to either reverse (Dhir and
Kulkarni 2007a, b; Socała et al. 2012d; Zomkowski et al.
2010, 2012) or enhance (Socała et al. 2012a, b; Socała et al.
2012c) or not to affect (Brink et al. 2008; Socała et al. 2012c)
the activity of some antidepressants in the forced swim test
in rodents. For this reason, we aimed to extend the studies on
other antidepressant drugs, namely sertraline, fluvoxamine,
citalopram, maprotiline, trazodone, and agomelatine. The
tested compounds vary in their mechanism of action.
Sertraline, fluvoxamine, and citalopram belong to the
SSRIs; maprotiline is a noradrenaline reuptake inhibitor;
trazodone is a mixed serotonin reuptake inhibitor and a 5-
HT2A/5-HT2C receptor antagonist; while agomelatine is a
melatonin receptor agonist and a 5-HT2C receptor antago-
nist. Although the main mode of action of sertraline,
fluvoxamine, and citalopram is the same (i.e., they selective-
ly inhibit the reuptake of serotonin), the drugs within this
class show few differences from one another. For example,
citalopram is the most selective inhibitor of serotonin reup-
take currently available (Bezchlibnyk-Butler et al. 2000),
while sertraline is metabolized into desmethylsertraline that
shows significantly higher selectivity towards noradrena-
line than serotonin transporters. Moreover, sertraline exerts
comparatively marked affinity for dopamine transporters
whereas fluvoxamine for sigma1 receptors (Millan 2006).
Table 1 Effect of treatments on the spontaneous locomotor activity in
mice
Treatment (mg/kg) Activity counts/4 min
a.
Control 1168 ± 170.2
Sertraline (20) 1420 ± 136.8
Sertraline (20) + sildenafil (20) 1173 ± 172.7
Fluvoxamine (40) 1293 ± 140.1
Fluvoxamine (40) + sildenafil (30) 1494 ± 177.7
Agomelatine (30) 826.4 ± 75.1
Agomelatine (30) + sildenafil (30) 279.9 ± 83.2***
b.
Control 1072 ± 78.7
Citalopram (25) 1326 ± 129.0
Citalopram (25) + sildenafil (30) 1053 ± 187.1
Maprotiline (40) 34.11 ± 12.2***
Maprotiline (40) + sildenafil (40) 48.78 ± 20.3***
Trazodone (10) 430.4 ± 97.0***
Trazodone (10) + sildenafil (40) 121.1 ± 39.6***
c.
Control 1156 ± 122.3
ECS 1220 ± 114.5
ECS + sildenafil (40), acute 992.9 ± 158.0
d.
Control 1146 ± 113.3
ECS 749.2 ± 103.2*
ECS + sildenafil (40), subchronic 627.1 ± 87.7**
Citalopram, maprotiline, and trazodone were injected 30 min before the
test, while sertraline, fluvoxamine, and agomelatine 60min before the test.
In all acute studies, sildenafil was administered i.p. 30 min before the test.
In subchronic studies, sildenafil was administered once daily for 14 con-
secutive days. All the drugs were injected i.p. Control animals received
vehicles only. Data are presented as means ± SEM
*p < 0.05; **p < 0.01; ***p < 0.001, vs. the respective control group
(one-way ANOVA followed by Tukey’s post hoc test)
Fig. 2 The effect of acute (a) and subchronic (b) sildenafil treatment on
the antidepressant efficacy of the repeated ECS in the forced swim test in
mice. In acute studies, sildenafil was administered i.p. 30 min before the
test. In subchronic studies, sildenafil was administered once daily for 14
consecutive days. Control and sham animals received vehicle only. Data
are presented asmeans + SEM. Each experimental group consisted of 10–
12 animals. *p < 0.05, ***p < 0.001, as compared to the control group;
###p < 0.001, as compared to the ECS-treated group (one-way ANOVA
followed by Tukey’s post hoc test)
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The results obtained in the present study showed that acute
sildenafil treatment potentiated the antidepressant-like action
of all of the studied drugs, regardless of their mechanism of
action. Despite the fact that trazodone and agomelatine were
devoid of anti-immobility action in the forced swim test, the
antidepressant-like effect was observed when these drugs
were co-administered with sildenafil.
Sildenafil is frequently used as a pharmacological tool for
studying the role of the NO/cGMP/PDE5 pathway in the
mechanism of action of other drugs. In many studies, silden-
afil, injected at a relatively small dose of 5 mg/kg, was shown
to abolish the antidepressant-like activity of various com-
pounds, indicating that these substances exert their effects in
the forced swim test by decreasing cGMP levels (Almeida
et al. 2006; Ghasemi et al. 2008; Ostadhadi et al. 2016; Haj-
Mirzaian et al. 2016; Khan et al. 2016). Here, we report that
sildenafil injected at higher doses (20–40 mg/kg) did not re-
verse the anti-immobility effects of antidepressant drugs. On
the contrary, it potentiated their action in the forced swim test,
which suggests that sildenafil may have opposite effects de-
pending on the dose used. Dual effects of the NO/cGMP path-
way modulators have been already reported. The NO donors
as well as NO synthase inhibitors can both increase and de-
crease the duration of immobility in a dose-dependent manner.
For instance, L-arginine (a NO precursor) when injected at low
doses increased the immobility time, while at higher doses, it
decreased the immobility time in the forced swim test (Inan
et al. 2004).
Although the forced swim test paradigm is the most widely
used animal model for studying antidepressant activity, it has
numerous limitations such as false positive or negative results
produced by drugs affecting locomotor activity (Petit-
Demouliere et al. 2005). In the present study, the anti-
immobility effects observed in the forced swim test were not
due to the general increase in locomotor activity in mice, as no
hyperlocomotion was observed. On the contrary, mice treated
with maprotiline and trazodone as well as with their combina-
tion with sildenafil exhibited a decrease in locomotor activity.
Sedative effects of maprotiline and trazodone were likely re-
lated to their ability to block histamine H1 receptors (Kanba
and Richelson 1986; Millan 2006). A significant decrease in
the locomotor activity after joint administration of
agomelatine and sildenafil but not agomelatine alone was ob-
served. The changes in the locomotor activity did not interfere
with the results obtained from the forced swim test.
Nevertheless, it appears that a combination of sildenafil with
agomelatine may produce some adverse effects, such as
sedation.
The interactions between sildenafil and the studied antide-
pressant drugs may have pharmacodynamic and/or pharmaco-
kinetic basis. In short, pharmacodynamic interaction occurs
when one drug alters the effect of another drug without affect-
ing its concentration in the blood or the site of action, whereas
pharmacokinetic drug–drug interaction occurs when one drug
changes the concentration of another drug by affecting its
absorption, distribution, metabolism, or excretion (Corrie
and Hardman 2014). The pharmacokinetic interaction be-
tween sildenafil and the studied antidepressants is probable
because sildenafil was reported to inhibit the cytochrome
P450 isoenzymes, such as CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1, and CYP3A4 (Hyland et al. 2001), most
of which are involved in the metabolism of antidepressant
drugs (Spina et al. 2008). In addition, the results of in vitro
studies indicate that sildenafil is an inhibitor of drug trans-
porters, such as ABCB1/P-gp, ABCG2/BCRP, ABCC4/
MRP4, ABCC5/MRP5, and ABCC10/MRP7, some of which
are present in the blood–brain barrier. However, up to date,
there are no convincing data confirming that this drug may
cause significant interactions with ABCB1/P-gp and ABCG2/
BCRP in vivo (Mei et al. 2015). Therefore, to evaluate the
potential pharmacokinetic interactions between the studied
antidepressant drugs and sildenafil, brain and serum concen-
trations of antidepressant drugs were determined. Data from
pharmacokinetic studies revealed an increased concentration
of fluvoxamine, citalopram, and agomelatine in the mouse
brain, i.e., at the site of action of antidepressant drugs, after
sildenafil co-administration. Additionally, sildenafil elevated
serum agomelatine level. The obtained results suggest that the
interactions between fluvoxamine, citalopram, or agomelatine
and sildenafil could have been pharmacokinetic in nature. The
changes in brain concentrations of these antidepressant drugs
Table 2 Effect of sildenafil on the concentrations of antidepressant
drugs
Treatment Drug concentration
Serum (ng/ml) Brain (μg/g)
Sertraline (20) 620.0 ± 77.84 5.90 ± 0.61
Sertraline (20) + sildenafil (20) 477.6 ± 74.42 5.77 ± 0.74
Fluvoxamine (40) 1286 ± 82.38 27.71 ± 2.40
Fluvoxamine (40) + sildenafil (30) 1070 ± 65.57 45.54 ± 2.25***
Citalopram (25) 4471 ± 477.1 32.46 ± 2.31
Citalopram (25) + sildenafil (30) 4291 ± 201.2 46.33 ± 3.93**
Maprotiline (40) 1836 ± 193.6 40.32 ± 1.81
Maprotiline (40) + sildenafil (40) 1894 ± 203.7 39.78 ± 4.31
Trazodone (10) 1186 ± 87.07 1.054 ± 0.15
Trazodone (10) + sildenafil (40) 1074 ± 56.04 1.247 ± 0.16
Agomelatine (30) 44.33 ± 5.68 0.042 ± 0.01
Agomelatine (30) + sildenafil (30) 72.34 ± 12.20* 0.157 ± 0.04**
Sildenafil, citalopram, maprotiline, and trazodone were injected 30 min,
while sertraline, fluvoxamine, and agomelatine 60 min before decapita-
tion. Each experimental group consisted of 9–12 animals. Data are pre-
sented as means ± SEM
*p < 0.05; **p < 0.01; ***p < 0.001, vs. the respective control group
(Student’s t test)
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caused by sildenafil co-administration might have been due to
an inhibition of enzymes involved in biotransformation of
antidepressants studied or their transport through the blood–
brain barrier. No alterations of brain and serum concentrations
of sertraline, maprotiline, and trazodone were noted. The in-
crease in antidepressant-like activity of these drugs was most
likely related to pharmacodynamic interactions (e.g., at the
receptor or signaling level).
Different types of results were expected in the present
study, namely the enhancement of the antidepressant activity
of the studied drugs by sildenafil co-administration, the rever-
sal of their anti-immobility action, or the lack of any effects.
Therefore, we investigated the effect of sildenafil administered
at several doses on the action of antidepressant drugs injected
at an effective dose. Further studies are required to better char-
acterize the type of interactions between sildenafil and the
studied antidepressant drugs as sildenafil injected alone (at a
dose of 60 mg/kg) was also shown to produce an anti-
immobility action in the forced swim test (Socała et al.
2016). For example, combinations of an ineffective dose of
sildenafil with an ineffective dose of antidepressant drugs
should be tested to confirm the presence of an additive/
synergistic interaction.
Since antidepressant medications often fail to adequately
treat severe depression, non-pharmacological interventions
for treatment-resistant depression have to be used. ECT re-
mains the most effective form of antidepressant therapy cur-
rently available. Despite a broad clinical use of ECT, the
mechanism underlying its efficacy is not fully understood
(Payne and Prudic 2009). Emerging data suggest that the in-
crease in the expression of brain-derived neurotrophic factor
(BDNF) may underlie the antidepressant effect of ECT
(Polyakova et al. 2015). Rosen et al. (2003) suggested a sig-
nificant role of NO in the mechanism of action of ECT. They
hypothesized that the involvement of NO in the long-term
potentiation, the N-methyl-D-aspartic acid (NMDA) receptor
activity, the hypothalamic–pituitary axis activity, and the reg-
ulation of cerebral blood flow may be critical in ECT’s effi-
ciency (Rosen et al. 2003). As sildenafil elevates BDNF level
(Puerta et al. 2010) and, what is more, it works via the NO/
cGMP/PDE5 pathway, we decided to investigate its influence
on the antidepressant-like efficacy of the repeated ECS in
mice. In the first experiment, acute administration of sildenafil
produced no changes in the anti-immobility action of the ECS
procedure. Therefore, in the next experiment, the influence of
subchronic (14 days) treatment with sildenafil was studied.
Interestingly, repeated administration of sildenafil dose depen-
dently decreased the antidepressant-like potential of the ECS
in mice. Sildenafil is considered to prolong the effects medi-
ated by NO, and the enhancement rather than suppression of
the antidepressant-like effect of ECS by sildenafil was expect-
ed. The observed effect could have been related to the activa-
tion of a negative feedback mechanism within the NO/cGMP/
PDE5 signaling pathway. The production of NO may have
been downregulated through negative feedback evoked by
accumulation of cGMP in response to the prolonged admin-
istration of sildenafil (Hotchkiss et al. 2005). Furthermore,
discontinuation of the 14-day continuous sildenafil treatment
may have led to withdrawal symptoms, such as increased
immobility time in the forced swim test. Possible addictive
effects of sildenafil use have not been extensively studied as
yet. Nevertheless, epidemiologic studies indicated that silden-
afil is sometimes abused in a recreational fashion. In addition,
animal studies showed rewarding properties of sildenafil in
the conditioned place preference paradigm (Tahsili-Fahadan
et al. 2006).
The effects observed in the forced swim test were not due
to the changes in locomotor activity. In acute studies, no
alterations in spontaneous locomotor activity were ob-
served. Unexpectedly, hypolocomotion was noticed in mice
subjected to the ECS procedure and injected with either ve-
hicle or sildenafil for 14 days. It is known that repeated i.p.
injections can pose a stress risk. Of note, different levels of
Fos immunoreactivity after stress induced by repeated i.p.
injection and handling in two strains of mice were reported,
which suggests that genetic background may also affect be-
havioral response to the injection stress and habituation pro-
cedure (Ryabinin et al. 1999). Based on our observation, it
seems that the ECS procedure and repeated i.p. injections
may produce different behavioral changes in comparison
with ECS treatment and acute i.p. injections. Further studies
are required to fully understand the mechanism underlying
the observed phenomenon. Nevertheless, since the de-
creased locomotor activity was observed in animals subject-
ed to the ECS procedure and injected with sildenafil as well
as in animals mice subjected to the ECS procedure alone, the
changes in locomotion did not interfere with the results from
the forced swim test.
To conclude, the present findings demonstrate for the first
time that sildenafil augments the activity of several antidepres-
sant drugs in the forced swim test in mice. No changes in brain
concentrations of sertraline, maprotiline, and trazodone sug-
gest that the interactions between sildenafil and these drugs
were pharmacodynamic in nature. In contrast, an increased
activity of fluvoxamine, citalopram, and agomelatine was re-
lated, at least in part, to their pharmacokinetic interactions
with sildenafil. However, caution should be taken in the ex-
trapolation of our results to humans because the biotransfor-
mation of the studied antidepressants may vary between mice
and humans. Moreover, we showed that acute treatment with
sildenafil did not influence the antidepressant-like effect of the
ECS procedure in mice, while subchronic (14 days) treatment
with this drug abolished the anti-immobility action of this
procedure in mice. Further studies are required to develop a
safe and effective antidepressant treatment in patients taking
sildenafil.
Naunyn-Schmiedeberg's Arch Pharmacol (2017) 390:339–349 347
Acknowledgements This study was supported by the Iuventus Plus
program (grant number IP2014 043373) from the Polish Ministry of
Science and Higher Education. The authors wish to thank Polpharma
(Starogard Gdański, Poland) for the generous gift of sildenafil.
Compliance with ethical standards The study was performed under
experimental protocols approved by the Ethical Committee of the
Medical University in Lublin. Housing and experimental procedures were
conducted in accordance with the European Union Directive of 22
September 2010 (2010/63/EU) and Polish legislation acts concerning
animal experimentation.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Almeida RC, Felisbino CS, Lopez MG, Rodrigues AL, Gabilan NH
(2006) Evidence for the involvement of L-arginine-nitric oxide-
cyclic guanosine monophosphate pathway in the antidepressant-
like effect of memantine in mice. Behav Brain Res 168:318–322
Bezchlibnyk-Butler K, Aleksic I, Kennedy SH (2000) Citalopram—a
review of pharmacological and clinical effects. J Psychiatry
Neurosci 25:241–254
Brink CB, Clapton JD, Eagar BE, Harvey BH (2008) Appearance of
antidepressant-like effect by sildenafil in rats after central muscarinic
receptor blockade: evidence from behavioural and neuro-receptor
studies. J Neural Transm 115:117–125
Corrie K, Hardman JG (2014) Mechanisms of drug interactions: pharma-
codynamics and pharmacokinetics. Anaesth Intensive Care Med 15:
305–308
Dadomo H, Parmigiani S, Nicolini Y, Freschini S, Gioiosa L, Patrelli TS,
Palanza P, Volpi R (2013) Repeated and chronic administration of
vardenafil or sildenafil differentially affects emotional and socio-
sexual behavior in mice. Behav Brain Res 253:103–112
Dhir A, Kulkarni SK (2007a) Involvement of L-arginine-nitric oxide-
cyclic guanosine monophosphate pathway in the antidepressant-
like effect of venlafaxine in mice. Prog Neuro-Psychopharmacol
Biol Psychiatry 31:921–925
Dhir A, Kulkarni SK (2007b) Involvement of nitric oxide (NO) signaling
pathway in the antidepressant action of bupropion, a dopamine re-
uptake inhibitor. Eur J Pharmacol 568:177–185
Farre JM, Fora F, Lasheras MG (2004) Specific aspects of erectile dys-
function in psychiatry. Int J Impot Res 16(Suppl 2):46–49
Ghasemi M, Sadeghipour H, Mosleh A, Sadeghipour HR, Mani AR,
Dehpour AR (2008) Nitr ic oxide involvement in the
antidepressant-like effects of acute lithium administration in the
mouse forced swimming test. Eur Neuropsychopharmacol 18:323–
332
Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC (2015) The
economic burden of adults with major depressive disorder in the
United States (2005 and 2010). J Clin Psychiatry 76:155–162
Haj-Mirzaian A, Kordjazy N, Amiri S, Haj-Mirzaian A, Amini-Khoei H,
Ostadhadi S, Dehpour A (2016) Involvement of nitric oxide-cyclic
guanosine monophosphate pathway in the antidepressant-like effect
of tropisetron and ondansetron in mice forced swimming test and tail
suspension test. Eur J Pharmacol 780:71–81
Hotchkiss AK, Pyter LM, Gatien ML, Wen JC, Milman HA, Nelson RJ
(2005) Aggressive behavior increases after termination of chronic
sildenafil treatment in mice. Physiol Behav 83:683–688
Hyland R, Roe EG, Jones BC, Smith DA (2001) Identification of the
cytochrome P450 enzymes involved in the N-demethylation of sil-
denafil. Br J Clin Pharmacol 51:239–248
Inan SY, Yalcin I, Aksu F (2004) Dual effects of nitric oxide in the mouse
forced swimming test: possible contribution of nitric oxide-
mediated serotonin release and potassium channel modulation.
Pharmacol Biochem Behav 77:457–464
Iosifescu DV, Bankier B, Fava M (2004) Impact of medical comorbid
disease on antidepressant treatment of major depressive disorder.
Curr Psychiatry Rep 6:193–201
Kanba S, Richelson E (1986) Antidepressant interactions with neuro-
transmitter receptors in vitro: prediction of potential side effects.
In: O'Brien RA (ed) Receptor binding in drug research. Marcel
Deker, Inc., New York, pp. 429–449
Kang HJ, Kim SY, Bae KY, Kim SW, Shin IS, Yoon JS, Kim JM (2015)
Comorbidity of depression with physical disorders: research and
clinical implications. Chonnam Med J 51:8–18
Khan MI, Ostadhadi S, Zolfaghari S, Ejtemaei MS, Hassanzadeh G,
Dehpour AR (2016) The involvement of NMDA receptor/NO/
cGMP pathway in the antidepressant like effects of baclofen in
mouse force swimming test. Neurosci Lett 612:52–61
Lopez-Munoz F, Alamo C (2009)Monoaminergic neurotransmission: the
history of the discovery of antidepressants from 1950s until today.
Curr Pharm Des 15:1563–1586
McCollister DH (2011) Screening pulmonary hypertension patients for
depression. Int J Clin Pract 65(Suppl 174):4–5
Mei XL, Yang Y, Zhang YJ, Li Y, Zhao JM, Qiu JG, Zhang WJ, Jiang
QW, XueYQ, ZhengDW, Chen Y, QinWM,WeiMN, Shi Z (2015)
Sildenafil inhibits the growth of human colorectal cancer in vitro and
in vivo. Am J Cancer Res 5:3311–3324
Millan MJ (2006) Multi-target strategies for the improved treatment of
depressive states: conceptual foundations and neuronal substrates,
drug discovery and therapeutic application. Pharmacol Ther 110:
135–370
Nurnberg HG, Hensley PL (2003) Sildenafil citrate for the management
of antidepressant-associated erectile dysfunction. J Clin Psychiatry
64(Suppl 10):20–25
Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh
R (2002) Depression, antidepressant therapies, and erectile dysfunc-
tion: clinical trials of sildenafil citrate (Viagra) in treated and untreat-
ed patients with depression. Urology 60:58–66
Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine
S (2003) Treatment of antidepressant-associated sexual dysfunc-
tion with sildenafil: a randomized controlled trial. JAMA 289:
56–64
Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S
(2008) Sildenafil treatment of women with antidepressant-
associated sexual dysfunction: a randomized controlled trial.
JAMA 300:395–404
Ostadhadi S, Khan MI, Norouzi-Javidan A, Chamanara M, Jazaeri F,
Zolfaghari S, Dehpour AR (2016) Involvement of NMDA recep-
tors and L-arginine/nitric oxide/cyclic guanosinemonophosphate
pathway in the antidepressant-like effects of topiramate in mice
forced swimming test. Brain Res Bull 122:62–70
Payne NA, Prudic J (2009) Electroconvulsive therapy: part I. A perspec-
tive on the evolution and current practice of ECT. J Psychiatr Pract
15:346–368
Petit-Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in
mice: a review of antidepressant activity. Psychopharmacology 177:
245–255
348 Naunyn-Schmiedeberg's Arch Pharmacol (2017) 390:339–349
PolyakovaM, Schroeter ML, Elzinga BM, Holiga S, Schoenknecht P, De
Kloet ER, Molendijk ML (2015) Brain-derived neurotrophic factor
and antidepressive effect of electroconvulsive therapy: systematic
review and meta-analyses of the preclinical and clinical literature.
PLoS One 10:e0141564
Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a
primary screening test for antidepressants. Arch Int Pharmacodyn
Ther 229:327–336
Puerta E, Hervias I, Barros-Minones L, Jordan J, Ricobaraza A,
Cuadrado-Tejedor M, Garcia-Osta A, Aguirre N (2010)
Sildenafil protects against 3-nitropropionic acid neurotoxicity
through the modulation of calpain, CREB, and BDNF. Neurobiol
Dis 38:237–245
Rosen RC, McKenna KE (2002) PDE-5 inhibition and sexual response:
pharmacological mechanisms and clinical outcomes. Annu Rev Sex
Res 13:36–88
Rosen Y, Reznik I, Sluvis A, Kaplan D,Mester R (2003) The significance
of the nitric oxide in electro-convulsive therapy: a proposed neuro-
physiological mechanism. Med Hypotheses 60:424–429
Ryabinin AE, Wang YM, Finn DA (1999) Different levels of Fos immu-
noreactivity after repeated handling and injection stress in two in-
bred strains of mice. Pharmacol Biochem Behav 63:143–151
Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC (2001)
Treatment of erectile dysfunction in menwith depressive symptoms:
results of a placebo-controlled trial with sildenafil citrate. Am J
Psychiatry 158:1623–1630
Socała K, Nieoczym D, Wyska E, Poleszak E, Wlaź P (2012a) Influence
of sildenafil on the antidepressant activity of bupropion and
venlafaxine in the forced swim test in mice. Pharmacol Biochem
Behav 103:273–278
Socała K, Nieoczym D, Wyska E, Poleszak E, Wlaź P (2012b) Sildenafil, a
phosphodiesterase type 5 inhibitor, enhances the activity of two atypical
antidepressant drugs,mianserin and tianeptine, in the forced swim test in
mice. Prog Neuro-Psychopharmacol Biol Psychiatry 38:121–126
Socała K, Nieoczym D,Wyska E, Poleszak E, Wlaź P (2012c) Sildenafil,
a phosphodiesterase type 5 inhibitor, enhances the antidepressant
activity of amitriptyline but not desipramine, in the forced swim test
in mice. J Neural Transm 119:645–652
Socała K, Nieoczym D,Wyska E, Poleszak E, Wlaź P (2012d) Sildenafil,
a phosphodiesterase type 5 inhibitor, reduces antidepressant-like
activity of paroxetine in the forced swim test in mice. Pharmacol
Rep 64:1259–1266
Socała K, Nieoczym D, Pierog M, Szuster-Ciesielska A, Wyska E,
Wlaź P (2016) Antidepressant-like activity of sildenafil follow-
ing acute and subchronic treatment in the forced swim test in
mice: effects of restraint stress and monoamine depletion. Metab
Brain Dis 31:1095–1104
Spina E, Santoro V, D'Arrigo C (2008) Clinically relevant pharmacoki-
netic drug interactions with second-generation antidepressants: an
update. Clin Ther 30:1206–1227
Tahsili-Fahadan P, Yahyavi-Firouz-Abadi N, Orandi AH, Esmaeili B,
Basseda Z, Dehpour AR (2006) Rewarding properties of sildenafil
citrate in mice: role of the nitric oxide-cyclic GMP pathway.
Psychopharmacology 185:201–207
Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K,
Suppiramaniam V, Dhanasekaran M (2007) Versatile effects of sil-
denafil: recent pharmacological applications. Pharmacol Rep 59:
150–163
Wang RC, Jiang FM, Zheng QL, Li CT, Peng XY, He CY, Luo J, Liang
ZA (2014) Efficacy and safety of sildenafil treatment in pulmonary
arterial hypertension: a systematic review. Respir Med 108:531–537
Zomkowski AD, Engel D, Gabilan NH, Rodrigues AL (2010)
Involvement of NMDA receptors and L-arginine-nitric oxide-
c y c l i c g uano s i n e monopho s ph a t e p a t hway i n t h e
antidepressant-like effects of escitalopram in the forced swim-
ming test. Eur Neuropsychopharmacol 20:793–801
Zomkowski AD, Engel D, CunhaMP, Gabilan NH, Rodrigues AL (2012)
The role of the NMDA receptors and L-arginine-nitric oxide-cyclic
guanosine monophosphate pathway in the antidepressant-like effect
of duloxetine in the forced swimming test. Pharmacol Biochem
Behav 103:408–417
Naunyn-Schmiedeberg's Arch Pharmacol (2017) 390:339–349 349
